Biogen Inc (BIIB.O)
Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion to license the Danish company's patents covering multiple sclerosis drugs, providing Biogen an insurance policy on future sales of Tecfidera, its blockbuster oral treatment for the disease.
* FORWARD PHARMA AGREES TO ENTER INTO SETTLEMENT AND LICENSE AGREEMENT WITH BIOGEN
Jan 17 Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to license the Danish company's patents covering multiple sclerosis drugs including Biogen's flagship drug, Tecfidera.
Jan 17 Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to gain access to the Danish company's intellectual property as it seeks to protect the patent life of its flagship multiple sclerosis drug, Tecfidera.
* Biogen and Forward Pharma agree to enter into settlement and license agreement
* Biogen spin-off Bioverativ commences when-issued trading of common stock
The U.S. Food and Drug Administration on Friday said it has approved Biogen Inc's drug to treat spinal muscular atrophy, the leading genetic cause of death in infants.
NEW YORK The surprise selection of Michel Vounatsos to run Biogen Inc signals a shift toward a more commercial management focus after years of targeting ambitious scientific gains, and likely keeps the U.S. biotech in play as a takeover target.
Biogen Inc, the U.S. drug maker focused on neurological, autoimmune and rare diseases, said on Monday it had appointed its chief commercial officer, Michel Vounatsos, as chief executive officer, ending a five-month search.
Gradually increasing the dose of Biogen Inc's experimental Alzheimer's disease drug appeared to reduce the risk of brain swelling compared to higher fixed doses, interim 12-month results from a small study released on Thursday showed.